Test Price
7,000 AED✅ Home Collection Available
Oncomine Tumor Mutation Burden (TMB) & Microsatellite Instability (MSI) Analysis in UAE | 7000 AED
Executive Summary & Core Metrics
Guaranteed Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS+Sanger sequencing.
Hospital-Based Collection: Tumor biopsy and blood draw performed at accredited medical facility; home collection is not available for this test.
Clinical Guidance: Complimentary telephonic post‑test interpretation with a clinical genomics specialist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This advanced genomic test precisely quantifies tumor mutational burden and microsatellite instability using ultra‑accurate next‑generation sequencing with Sanger confirmation, guiding immunotherapy and targeted therapy decisions with high confidence.
Test Overview & Methodology
The Oncomine TMB & MSI Analysis is a comprehensive next‑generation sequencing test that quantifies tumor mutational burden and microsatellite instability status from tumor tissue and blood, guiding immunotherapy and targeted therapy decisions.
| Feature | Our Test – TMB+MSI NGS Panel | Closest Alternative (Standard PCR‑Based MSI) |
|---|---|---|
| Precision | High‑throughput NGS with orthogonal Sanger validation; detects low‑frequency variants | PCR‑based, limited to pre‑defined microsatellite markers; missing rare instability patterns |
| Methodology | Next‑Generation Sequencing (NGS) + Sanger Sequencing confirmation | PCR fragment analysis |
| Turnaround Time | 2–3 weeks | 4–6 weeks |
| Actionable Insights | Simultaneous TMB (mut/Mb) + MSI status; correlates with ICI response across tumor types | Only MSI‑H/dMMR status; no TMB data |
Physician Insight & Safety Protocols
“As a specialist in diagnostic radiology, I understand that awaiting genomic results can be stressful. This test provides critical insights into your tumor’s genomic landscape, but it must be interpreted together with imaging and clinical findings. Always discuss results with your oncology team before altering treatment.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Warning
Do not discontinue any prescribed medication without consulting your doctor. Test results alone are not a substitute for a full clinical assessment.
Exclusion Criteria & Emergency Red Flags
- Prescription Requirement: This test must be ordered by a licensed physician. Not intended for surgery clearance, pregnancy‑related decisions, or travel abroad.
- Sample Adequacy: Requires suitable tumor tissue (biopsy/resection) and paired peripheral blood; samples with necrosis > 30% may be rejected.
- ER Red Flags: If you experience severe pain, bleeding at biopsy site, or sudden clinical deterioration, seek emergency care immediately. Do not wait for genetic test results.
- Pregnancy & Paediatrics: Not validated for fetal testing or minors without explicit pediatric oncology consultation.
Patient FAQ & Clinical Guidance
1. What is the purpose of TMB & MSI testing?
TMB and MSI testing identifies tumor genomic instability, predicting response to immune checkpoint inhibitors like pembrolizumab. This information helps oncologists choose the most effective immunotherapy for your cancer type.
2. How is the test performed and what is the turnaround time?
The test uses Next‑Generation Sequencing on tumor biopsy tissue and a paired blood sample. Results are available within 2–3 weeks from sample receipt at our ISO‑accredited laboratory.
3. Is this test covered by insurance in the UAE?
Many UAE insurers cover TMB/MSI testing for approved cancer types. We offer direct billing verification via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with UAE federal laws governing health data and patient privacy:
- Data Protection: Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health ICT: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability: Federal Decree‑Law No. 4 of 2016 on Medical Liability ensures patient safety and informed consent.
- Certification: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
All genomic data is encrypted and stored securely within the UAE. Your information is never shared without your explicit consent.
Clinical & Logistical Metadata
| Test Name | Oncomine Tumor Mutation Burden (TMB) & Microsatellite Instability (MSI) Analysis |
| Price (AED) | 7,000 AED |
| Turnaround Time | 2–3 weeks |
| Sample Type / Matrix | Tumor tissue (biopsy / resection) and peripheral blood – Hospital‑only collection |
| Methodology Used | Next‑Generation Sequencing (NGS) + Sanger Sequencing confirmation |
| ICD-10-CM Code | C80.1, Z85.9 |
| LOINC Code | 96317-7, 94520-1 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians